Bart Keymeulen

7.8k total citations
155 papers, 4.3k citations indexed

About

Bart Keymeulen is a scholar working on Surgery, Genetics and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Bart Keymeulen has authored 155 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Surgery, 109 papers in Genetics and 101 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Bart Keymeulen's work include Pancreatic function and diabetes (106 papers), Diabetes and associated disorders (104 papers) and Diabetes Management and Research (84 papers). Bart Keymeulen is often cited by papers focused on Pancreatic function and diabetes (106 papers), Diabetes and associated disorders (104 papers) and Diabetes Management and Research (84 papers). Bart Keymeulen collaborates with scholars based in Belgium, Netherlands and United States. Bart Keymeulen's co-authors include Daniël Pipeleers, Frans Gorus, Chantal Mathieu, Pieter Gillard, Bart O. Roep, Robert Hilbrands, Christophe De Block, Ilse Weets, Gaby Duinkerken and Evy Vandemeulebroucke and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Blood.

In The Last Decade

Bart Keymeulen

151 papers receiving 4.1k citations

Peers

Countries citing papers authored by Bart Keymeulen

Since Specialization

Citations

This map shows the geographic impact of Bart Keymeulen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Keymeulen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Keymeulen more than expected).

Fields of papers citing papers by Bart Keymeulen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Keymeulen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Keymeulen. The network helps show where Bart Keymeulen may publish in the future.

Co-authorship network of co-authors of Bart Keymeulen

This figure shows the co-authorship network connecting the top 25 collaborators of Bart Keymeulen. A scholar is included among the top collaborators of Bart Keymeulen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart Keymeulen. Bart Keymeulen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Continuous glucose monitor metrics from five studies identify participants at risk for type 1 diabetes development 2025 ·Diabetologia ·Peter Calhoun, (unknown), Andrea K. Steck, Brigitte I. Frohnert, Mark A. Herman, Bart Keymeulen, Riitta Veijola, Jorma Toppari, (unknown), Frans Gorus, Mark A. Atkinson, Darrell M. Wilson, Susan L. Pietropaolo, Roy W. Beck	0
2	Repeated OGTT Versus Continuous Glucose Monitoring for Predicting Development of Stage 3 Type 1 Diabetes: A Longitudinal Analysis 2025 ·Diabetes Care ·(unknown), Bart Keymeulen, Ursule Van de Velde, (unknown), Bruno Lapauw, Christophe De Block, Pieter Gillard, (unknown), Eric V. Balti, (unknown), Willem Staels, (unknown), Marieke den Brinker, (unknown), (unknown), (unknown), Frans Gorus	5
3	Cost–utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium 2024 ·Diabetologia ·(unknown), (unknown), Sara Charleer, John J. Isitt, Stéphane Roze, Christophe De Block, Toon Maes, Gerd Vanhaverbeke, Frank Nobels, Bart Keymeulen, Chantal Mathieu, Jeroen Luyten, Pieter Gillard, Nick Verhaeghe	1
4	First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes 2023 ·BMC Medicine ·Jean Van Rampelbergh, Peter Achenbach, Richard David Leslie, Mohammad Alhadj Ali, Colin Dayan, Bart Keymeulen, Katharine R. Owen, (unknown), (unknown), Vincent Carlier, (unknown), (unknown), Nicolas Bovy, Luc VanderElst, Marcelle Van Mechelen, Pierre Vandepapelière, Christian Boîtard	13
5	Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2 , in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial 2022 ·Diabetes Obesity and Metabolism ·Lorenzo Piemonti, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose, Paolo Pozzilli, Francesco Giorgino, Efisio Cossu, L. Daffonchio, (unknown), Pier Adelchi Ruffini, Anna Rita Maurizi, (unknown), Marcello Allegretti	36
6	Function and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients 2021 ·American Journal of Transplantation ·(unknown), (unknown), Robert Hilbrands, Ursule Van de Velde, (unknown), Geert Stangé, (unknown), (unknown), Zhidong Ling, Bart O. Roep, Pieter Gillard, Daniël Pipeleers, Bart Keymeulen, Daniel Jacobs‐Tulleneers‐Thevissen	9
7	Quality of life versus glycaemic variability and time in range in people with type 1 diabetes : sub study of the RESCUE-trial 2020 ·Ghent University Academic Bibliography (Ghent University) ·Pieter Gillard, (unknown), (unknown), Sara Charleer, (unknown), Kristien J. Ledeganck, Bart Keymeulen, Laurent Crenier, Régis Radermecker, Bruno Lapauw, Chris Vercammen, Frank Nobels, Chantal Mathieu, Christophe De Block	1
8	A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes 2020 ·Diabetologia ·Bart Keymeulen, André van Maurik, David R. Inman, (unknown), René McLaughlin, Rachel Gittelman, Bart O. Roep, Pieter Gillard, Robert Hilbrands, Frans Gorus, Chantal Mathieu, Ursule Van de Velde, Nicolas Wisniacki, Antonella Napolitano	38
9	Formation of amyloid in encapsulated human pancreatic and human stem cell-generated beta cell implants 2020 ·American Journal of Transplantation ·(unknown), (unknown), Geert Stangé, (unknown), (unknown), (unknown), Zhidong Ling, Robert Hilbrands, Pieter Gillard, Bart Keymeulen, Evert Kroon, Gunilla T. Westermark, Daniel Jacobs‐Tulleneers‐Thevissen, Daniël Pipeleers	3
10	Combined Analysis of GAD65, miR-375, and Unmethylated Insulin DNA Following Islet Transplantation in Patients With T1D 2018 ·The Journal of Clinical Endocrinology & Metabolism ·Sarah Roels, (unknown), Sarah A. Tersey, Geert Stangé, Dieter De Smet, Eric V. Balti, Pieter Gillard, Bart Keymeulen, Zhidong Ling, Daniël Pipeleers, Frans Gorus, Raghavendra G. Mirmira, Geert A. Martens	11
11	Boost for Alginate Encapsulation in Beta Cell Transplantation 2016 ·Trends in Endocrinology and Metabolism ·Daniël Pipeleers, Bart Keymeulen	11
12	Pre-existing insulin autoantibodies predict efficacy of otelixizumab in preserving residual beta cell function in recent-onset type 1 diabetes 2014 ·Diabetologia ·(unknown), Bart Keymeulen, Leonard Kaufman, (unknown), Eric V. Balti, Ursule Van de Velde, Patrick Goubert, Katrijn Verhaeghen, Ilse Weets, Daniël Pipeleers, Frans Gorus	4
13	Anticorps monoclonaux en diabétologie: jusqu'au bout du rêve? 2009 ·VUBIR (Vrije Universiteit Brussel) ·(unknown), Bart Keymeulen, Cynthia Mathieu, André Scheen	0
14	AUTOREACTIVE CD8 T CELLS ASSOCIATED WITH BETA-CELL DESTRUCTION IN TYPE 1 DIABETES 2005 ·Endocrine Journal ·(unknown), (unknown), (unknown), G. Michel, Ferry Ossendorp, (unknown), Bart Keymeulen, Daniël Pipeleers, (unknown), (unknown)	8
15	SPIROMETRIC CHANGES AT HIGH ALTITUDE: THE SHISAPANGMA EXPERIENCE 2005 ·CHEST Journal ·Marc Meysman, Bart Keymeulen, E. Eeckhout, Marc Noppen, Walter Vincken	2
16	Single and Multiple Doses of MK-0767 (KRP-297) reduce Free Fatty Acids (FFA) and Lipids in Healthy Subjects. 2003 ·Diabetes ·John Wagner, (unknown), (unknown), Jody C Miller, Dominique Ballaux, Martin De Smet, Keith Gottesdiener, Bart Keymeulen	1
17	HLA-DQ restricted progression to clinical onset in antibody-positive first degree relatives of type 1 diabetic patients 2002 ·Diabetologia ·(unknown), Katelijn Decochez, (unknown), (unknown), Ilse Weets, I. De Leeuw, Bart Keymeulen, Chantal Mathieu, R. Rottiers, Daniël Pipeleers	1
18	Le diabete de type 1: Une maladie auto-immune heterogene, predictible, evitable, guerissable? 1998 ·Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) ·Frans Gorus, Harry Dorchy, Bart Keymeulen, Christina Vandewalle, Katelijn Decochez, Ilse Weets, Frederic Winnock	1
19	Progressive Diaphyseal Dysplasia (Camurati-Engelmann??s Disease) 1994 ·Clinical Nuclear Medicine ·(unknown), Bart Keymeulen, Axel Bossuyt, Guido Somers, Leon Verbruggen	7
20	Immunointervention in Type 1 (Insulin-Dependent) Mellitus Diabetes 1993 ·Acta Clinica Belgica ·Bart Keymeulen, Gino R. Somers	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact